Patents by Inventor Oleksandr Buzko

Oleksandr Buzko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11370793
    Abstract: Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: June 28, 2022
    Assignee: NantNeuro, LLC
    Inventors: Varghese John, Oleksandr Buzko, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska
  • Publication number: 20220024935
    Abstract: Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.
    Type: Application
    Filed: September 2, 2021
    Publication date: January 27, 2022
    Inventors: Varghese John, Oleksandr Buzko, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska
  • Patent number: 10736884
    Abstract: Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: August 11, 2020
    Assignees: NantBio, Inc., NantOmics, LLC, Nant Holdings IP, LLC
    Inventors: Shahrooz Rabizadeh, Oleksandr Buzko, Paul Weingarten, Heather McFarlane, Connie Tsai, Stephen Charles Benz, Kayvan Niazi, Patrick Soon-Shiong
  • Patent number: 10668076
    Abstract: The invention relates to a method of modeling K-Ras proteins with one or more mutations that result in constitutive activity, and identifying compounds that inhibit interactions among activated K-Ras proteins and their upstream and downstream effectors.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: June 2, 2020
    Assignee: NantBio, Inc.
    Inventors: Shahrooz Rabizadeh, Kayvan Niazi, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Publication number: 20200069654
    Abstract: Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.
    Type: Application
    Filed: June 14, 2019
    Publication date: March 5, 2020
    Applicants: NANTBIO, INC., NANTOMICS, LLC, NANT HOLDINGS IP, LLC
    Inventors: Shahrooz RABIZADEH, Oleksandr BUZKO, Paul WEINGARTEN, Heather MCFARLANE, Connie TSAI, Stephen Charles BENZ, Kayvan NIAZI, Patrick SOON-SHIONG
  • Publication number: 20200038482
    Abstract: Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.
    Type: Application
    Filed: October 7, 2019
    Publication date: February 6, 2020
    Applicant: Chan Soon-Shiong Nanthealth Foundation
    Inventors: Kayvan NIAZI, Shahrooz RABIZADEH, Justin GOLOVATO, Oleksandr BUZKO, Anne-Laure LE NY, Patrick SOON-SHIONG
  • Patent number: 10525040
    Abstract: Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: January 7, 2020
    Assignees: NantBio, Inc., NantOmics, LLC, Nant Holdings IP, LLC
    Inventors: Shahrooz Rabizadeh, Oleksandr Buzko, Paul Weingarten, Heather McFarlane, Connie Tsai, Stephen Charles Benz, Kayvan Niazi, Patrick Soon-Shiong
  • Patent number: 10434142
    Abstract: Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: October 8, 2019
    Assignee: Chan Soon-Shiong Nanthealth Foundation
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Oleksandr Buzko, Anne-Laure Le Ny, Patrick Soon-Shiong
  • Patent number: 10350225
    Abstract: Compositions, compounds, and methods with significant antiviral effect against RNA viruses and especially orthomyxoviruses are contemplated, and target the viral promoter that is formed by the 5? and 3?-UTR sequences of the viral genome.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: July 16, 2019
    Assignee: Nant Holdings IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure Le Ny, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Publication number: 20190077766
    Abstract: Selected compounds, compositions, and methods for inhibiting BACE are presented that have relatively high selectivity towards APP via interaction of the inhibitor with both BACE and APP.
    Type: Application
    Filed: August 29, 2016
    Publication date: March 14, 2019
    Inventors: Varghese John, Oleksandr Buzko, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska
  • Publication number: 20190048012
    Abstract: Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.
    Type: Application
    Filed: August 29, 2016
    Publication date: February 14, 2019
    Inventors: Varghese John, Oleksandr Buzko, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska
  • Patent number: 10076529
    Abstract: Compositions, compounds, and methods with significant antiviral effect against RNA viruses and especially orthomyxoviruses are contemplated, and target the viral promoter that is formed by the 5? and 3?-UTR sequences of the viral genome.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: September 18, 2018
    Assignee: NANT HOLDINGS IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure Le Ny, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Publication number: 20180185335
    Abstract: Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.
    Type: Application
    Filed: June 29, 2016
    Publication date: July 5, 2018
    Applicant: NANTBIO, INC.
    Inventors: Shahrooz RABIZADEH, Oleksandr BUZKO, Paul WEINGARTEN, Heather MCFARLANE, Connie TSAI, Stephen Charles BENZ, Kayvan NIAZI, Patrick SOON-SHIONG
  • Patent number: 9987282
    Abstract: Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: June 5, 2018
    Assignee: NANT HOLDINGS IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure LeNy, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Publication number: 20180117118
    Abstract: Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 3, 2018
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Oleksandr Buzko, Anne-Laure Le Ny, Patrick Soon-Shiong
  • Patent number: 9884087
    Abstract: Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: February 6, 2018
    Assignee: CHAN SOON-SHIONG NANTHEALTH FOUNDATION
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Oleksandr Buzko, Anne-Laure LeNy, Patrick Soon-Shiong
  • Publication number: 20170360925
    Abstract: Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
    Type: Application
    Filed: August 31, 2017
    Publication date: December 21, 2017
    Applicant: Nant Holdings IP, LLC
    Inventors: Kayvan NIAZI, Shahrooz RABIZADEH, Justin GOLOVATO, Patrick Soon-Shiong, Anne-Laure LE NY, Oleksandr BUZKO
  • Patent number: 9750805
    Abstract: Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: September 5, 2017
    Assignee: Nant Holdings IP, LLC.
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Patrick Soon-Shiong, Anne-Laure Le Ny, Oleksandr Buzko
  • Patent number: 9687491
    Abstract: The invention relates to a method of modeling K-Ras proteins with one or more mutations that result in constitutive activity, and identifying compounds that inhibit interactions among activated K-Ras proteins and their upstream and downstream effectors.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: June 27, 2017
    Assignee: NantBioscience, Inc.
    Inventors: Shahrooz Rabizadeh, Kayvan Niazi, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Publication number: 20170128568
    Abstract: Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
    Type: Application
    Filed: September 14, 2016
    Publication date: May 11, 2017
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Patrick Soon-Shiong, Anne-Laure Le Ny, Oleksandr Buzko